RBC Capital Initiates Coverage On Dyne Therapeutics with Outperform Rating, Announces Price Target of $45

Benzinga · 11/26 10:02
RBC Capital analyst Luca Issi initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Outperform rating and announces Price Target of $45.